Claims for Patent: 12,090,140

Summary for Patent: 12,090,140

Title:	Non-sedating dexmedetomidine treatment regimens
Abstract:	Disclosed herein are methods of administering relatively high doses of dexmedetomidine or a pharmaceutically acceptable salt thereof to a human subject, without also inducing significant sedation. The disclosed methods are particularly suitable for the treatment of agitation, especially when associated with neurodegenerative and/or neuropsychiatric diseases such as schizophrenia, bipolar illness such as bipolar disorder or mania, dementia, depression, or delirium.
Inventor(s):	Vasukumar KAKUMANU, David Christian HANLEY, Frank Yocca, Chetan Dalpatbhai LATHIA, Lavanya Rajachandran, Robert Risinger
Assignee:	Bioxcel Therapeutics Inc
Application Number:	US18/526,686
Patent Claims:	1. A method of treating agitation associated with schizophrenia or bipolar I or II disorder in a human subject comprising: administering a first dose of dexmedetomidine or a pharmaceutically acceptable salt thereof in an oromucosal formulation to the human subject; optionally administering a second dose of dexmedetomidine or a pharmaceutically acceptable salt thereof in an oromucosal formulation that is administered to the human subject at least two hours after and within 24 hours of the first dose and wherein the second dose is 60 mcg of dexmedetomidine; optionally administering a third dose of dexmedetomidine or a pharmaceutically acceptable salt thereof in an oromucosal formulation that is administered to the human subject at least two hours after the second dose and within 24 hours of the first dose and wherein the third dose is 60 mcg of dexmedetomidine; wherein the human subject has a severe hepatic impairment and the agitation is mild or moderate; and wherein the first dose is 60 mcg of dexmedetomidine or the equivalent amount of a pharmaceutically acceptable salt thereof; wherein the maximum daily dose is 180 mcg. 2. The method of claim 1, wherein the oromucosal formulation further comprises at least one water-soluble polymer. 3. The method of claim 2, wherein the at least one water-soluble polymer is selected from the group consisting of hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxyethyl cellulose, carboxy methylcellulose, methylcellulose, polyethylene oxide (PEO), and mixtures thereof. 4. The method of claim 3, wherein the at least one water-soluble polymer is hydroxypropyl cellulose. 5. The method of claim 1, wherein the second dose of dexmedetomidine or a pharmaceutically acceptable salt thereof is administered and is 60 mcg of dexmedetomidine or the equivalent amount of a pharmaceutically acceptable salt thereof. 6. The method of claim 5, wherein the third dose of dexmedetomidine or a pharmaceutically acceptable salt thereof is administered and is 60 mcg of dexmedetomidine or the equivalent amount of a pharmaceutically acceptable salt thereof.